Evaluation the effect of asafoetida in the treatment of coronavirus infection

Evaluation the effect of asafoetida on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200413047053N1

Enrollment

Registered

2020-04-15

Start date

2020-04-20

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Covid-19

Interventions

Intervention 1: Intervention group1: In addition to the standard treatment regimen for covid-19, capsules which have aqueous 300 mg of Khorasan asafoetida will be given once a day for 2 weeks. asafoet

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Fever cough Myalgia lymphopenia CRP positive

Exclusion criteria

Exclusion criteria: Sensitivity to asafoetida and it derivatives Patients with hepatic disfunction Patients with renal disfunction Patients with respiratory disorders Patients who take cytotoxic or corticosteroid drugs Nursing women pregnant women

Design outcomes

Primary

Measure	Time frame
Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.	—

Secondary

Measure	Time frame
CRP level. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Iranshahi

Mashhad University of Medical Sciences

iranshahim@mums.ac.ir+98 51 3180 1256

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026